{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:20:16Z","timestamp":1790014816285,"version":"4.0.1"},"reference-count":49,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare intraocular pressure (IOP), ocular surface disease (OSD) parameters, and safety in patients with open-angle glaucoma (OAG)\/ocular hypertension (OH) and concurrent OSD treated with preservative-free latanoprost 0.005% cationic emulsion (PF-latanoprost-E) or travoprost-Z 0.004% ophthalmical solution containing a soft preservative system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with OAG\/OH and OSD were randomized to treatment with PF-latanoprost-E or travoprost-Z nightly for 3 months. Outcomes included mean diurnal IOP reduction; OSD endpoints, including symptom improvement, tear break-up time (TBUT), and corneal fluorescein staining (CFS) score; and safety after 1 and 3 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 105 patients were randomized, 51 to PF-latanoprost-E and 54 to travoprost-Z. IOP reductions (LS mean differences) at 3 months were numerically greater in the PF-latanoprost-E than in the travoprost-Z group at 8AM (7.2 versus 6.0 mmHg), 10AM (6.7 versus 5.9 mmHg), and 4PM (6.0 versus 5.4 mmHg). LS mean changes in IOP from baseline in both groups at 1 and 3 months, however, were comparable. Mean \u00b1 SD CFS scores on the Ora scale at month 3 showed significantly greater reductions in the PF-latanoprost-E than in the travoprost-Z group (\u20131.07\u2009\u00b1\u20091.863 versus \u20130.16\u2009\u00b1\u20092.553\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0461). The mean TBUT at month 3 showed similar improvements in both groups (1.1 versus 1.0 s,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05). OSD symptoms improved but did not differ significantly in the two groups. Overall safety was comparable in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>PF-latanoprost-E effectively and safely lowered IOP and improved OSD parameters in patients with OAG\/OH. These findings provide evidence for the beneficial effects of this new formulation of latanoprost in glaucoma patients with OSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2024.0029","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T10:02:12Z","timestamp":1723802532000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study"],"prefix":"10.1177","volume":"40","author":[{"given":"Jason","family":"Bacharach","sequence":"first","affiliation":[{"name":"North Bay Eye Associates, Petaluma, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene B.","family":"McLaurin","sequence":"additional","affiliation":[{"name":"Total Eye Care, P.A., Memphis, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-2485","authenticated-orcid":false,"given":"Steven","family":"Silverstein","sequence":"additional","affiliation":[{"name":"Silverstein Eye Centers, Kansas City, Missouri, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Amrane","sequence":"additional","affiliation":[{"name":"Santen Pharmaceuticals, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Sebastien","family":"Garrigue","sequence":"additional","affiliation":[{"name":"Santen Pharmaceuticals, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlia","family":"Ismail","sequence":"additional","affiliation":[{"name":"Santen Pharmaceuticals, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Flynn","sequence":"additional","affiliation":[{"name":"R and R Eye Research, LLC, San Antonio, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Catiolanze Phase 2 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18469"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62111-5"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2022.2041041"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02781.x"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0133"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181c325b2"},{"issue":"3","key":"e_1_3_5_9_2","first-page":"539","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn JS","year":"2017","unstructured":"Wolffsohn JS, , Arita R, , Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Could Surf, 2017; 15(3):539\u2013574; doi: 10.1016\/j.jtos.2017.05.001","journal-title":"Could Surf"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12012"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000133997.07144.9e"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01668-x"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1586\/17469899.4.1.59"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210901900409"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0159"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2019.29000"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2018.0134"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000301"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.05.013"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.022"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joco.2017.09.002"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.5301\/EJO.2010.6112"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0245"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e318255a7f8"},{"key":"e_1_3_5_27_2","first-page":"1690","article-title":"Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: An in\u00a0vivo toxicity assay","volume":"15","author":"Liang H","year":"2009","unstructured":"Liang H, , Baudouin C, , Faure MO, et al. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: An in\u00a0vivo toxicity assay. Mol Vis, 2009; 15:1690\u20131699.","journal-title":"Mol Vis"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/604204"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2022.0155"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02773.x"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071558"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2020.0011"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e318264cd68"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001041"},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"3837471","DOI":"10.1155\/2022\/3837471","article-title":"Cost-utility analysis of STN1013001, a latanoprost cationic emulsion, versus other latanoprost formulations (latanoprost) in open-angle glaucoma or ocular hypertension and ocular surface disease in France","volume":"2022","author":"Lazzaro C","year":"2022","unstructured":"Lazzaro C, , van Steen C, , Aptel F, et al. Cost-utility analysis of STN1013001, a latanoprost cationic emulsion, versus other latanoprost formulations (latanoprost) in open-angle glaucoma or ocular hypertension and ocular surface disease in France. J Ophthalmol, 2022; 2022:3837471; doi: 10.1155\/2022\/3837471","journal-title":"J Ophthalmol"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S351013"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2161515"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.08.017"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-023-00853-5"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000265"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.04.041"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S112711"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0151-7"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1017467"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2019.38"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0014-7"},{"key":"e_1_3_5_47_2","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/ICL.0000000000000405","article-title":"The effects of latanoprost with benzalkonium chloride versus travoprost with SofZia on the ocular surface","volume":"44","author":"Rahmatnejad K","year":"2017","unstructured":"Rahmatnejad K, , Rapuano CJ, , Ichhpujani P, et al. The effects of latanoprost with benzalkonium chloride versus travoprost with SofZia on the ocular surface. Eye Contact Lens, 2017; 44 Suppl 2:S93\u2013S98; doi: 10.1097\/ICL.0000000000000405","journal-title":"Eye Contact Lens"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100916"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000695"},{"key":"e_1_3_5_50_2","unstructured":"ClinicalTrials.gov. A Phase III Multinational Multicenter Investigator-Masked Randomised Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan\u00ae in Patients With Open-Angle Glaucoma or Ocular Hypertension. 2023. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04133311 [Last accessed: June1 2023]."}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2024.0029","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:46:22Z","timestamp":1777646782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2024.0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["10.1089\/jop.2024.0029"],"URL":"https:\/\/doi.org\/10.1089\/jop.2024.0029","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}